market access

News

Ionis' FCS drug approved in EU, launch due in Germany

Ionis Pharmaceuticals’ RNA-targeted drug Waylivra has been conditionally approved in Europe for the devastating ultra-rare disease Familial Chylomicronemia Syndrome (FCS).

News

Catalyst shares dive amid speculation about 'off-label' rare...

Shares in Catalyst Pharmaceuticals have dived after the US regulator approved a potential competitor to its rare disease drug Firdapse, which has been at the centre of a drug pricing row.

News

UK government revamps efforts to hasten access to new drugs

The UK government has announced a major revamp of its efforts to get innovative new medicines and therapies through clinical development and to the market.

News

Roche's blockbuster breast cancer drug Herceptin

Sandoz strikes deal with EirGenix for Herceptin biosimilar

Sandoz has struck a deal with Taiwan-based EirGenix to market a late-stage biosimilar of Roche’s breast cancer blockbuster Herceptin.

News

NHS trumpets Hep C deal, quietly drops 2025 elimination targ...

NHS England has announced a deal with AbbVie, Gilead, and Merck, Sharpe and Dohme (MSD) that aims to eliminate hepatitis C from the country - although it has had to drop a 2025 target

Digital

Deep Dive: Access and Commercialisation

In this issue of Deep Dive we explore the ever present issues of market access and commercialisation, analysing recent changes in China, England and the US and asking how pharma can work wi

Ionis' FCS drug approved in EU, launch due in Germany

Catalyst shares dive amid speculation about 'off-label' rare...

UK government revamps efforts to hasten access to new drugs

Sandoz strikes deal with EirGenix for Herceptin biosimilar

NHS trumpets Hep C deal, quietly drops 2025 elimination targ...

Deep Dive: Access and Commercialisation

Dexcom is first to join FDA/CMS health tech pilot

Discover a new era of healthcare panel engagement: Grounded ...

market access

Editor's Picks